Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2352Neoplasms 1707Prostatic Neoplasms 1197Lung Neoplasms 923Colorectal Neoplasms 882Carcinoma, Non-Small-Cell Lung 867Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 577Multiple Myeloma 549Carcinoma, Hepatocellular 516Brain Neoplasms 513Neoplasm Metastasis 459Head and Neck Neoplasms 454Melanoma 414Ovarian Neoplasms 413Glioblastoma 402Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 375Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 361Rectal Neoplasms 341Recurrence 336Sarcoma 325Hematologic Neoplasms 323Colonic Neoplasms 323Lymphoma 319Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 283Urinary Bladder Neoplasms 281Glioma 278

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastric and Gastroesophageal Junction Adenocarcinoma × 1 year × Clear all
NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Yonsei University

Phase 1/2 Active not recruiting
75 enrolled
Gastrointestinal

Gastric and Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡